The clinical dosage range spans 2.510 mg per subcutaneous injection, titrated over 4 weeks before reaching a maintenance dose of 510 mg, five times weekly
Because Dihexa activates HGF/c-Met signaling , and this pathway is also involved in some types of tumor progression, caution is advised in: Patients with active cancers History of certain malignancies No human data confirms a cancer risk, but Dihexa is best avoided in patients with cancer unless under strict clinical supervision
Thorn and Aspenberg, 1993
Further, they proved IGF1 could activate different signaling pathways in diverse CNS areas
Weight works that way as well. About the Experts Lydia Alexander, M.D., is an internal medicine physician with board certification in obesity medicine
Privacy Policy Data Protection at NovaCell NovaCell Privacy Policy: how we process personal data in accordance with the EU GDPR and the Swiss nDSG